{"id":8573,"date":"2025-04-01T16:57:09","date_gmt":"2025-04-01T14:57:09","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=8573"},"modified":"2025-07-04T17:01:13","modified_gmt":"2025-07-04T15:01:13","slug":"maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/","title":{"rendered":"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France."},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"d96716695\">Abstract<\/h2>\n\n\n\n<p>This nationwide cohort study provides a comprehensive overview of maternal and perinatal outcomes associated with sickle cell disease (SCD) during pregnancy. Using the French national health database, all singleton pregnancy-related hospital discharges from 2013 to 2020 in women aged 15\u201355 (<em>n<\/em>\u2009=\u20095\u2009752\u2009080) were selected. Of these, 1022 births were to women with SCD, 308 of whom were on long-term treatment, that is, hydroxyurea (HU) and\/or transfusion programme. Pregnancies with SCD were more likely to involve pre-eclampsia (9.6% vs. 1.7%; <em>p<\/em>\u2009&lt;\u20090.001), pulmonary embolism (0.70% vs. 0.02%; <em>p<\/em>\u2009&lt;\u20090.001), caesarean sections (52.8% vs. 18.2%; <em>p<\/em>\u2009&lt;\u20090.001) and postpartum haemorrhage (8.3% vs. 4.1%; <em>p<\/em>\u2009&lt;\u20090.001) compared to pregnancies without SCD. Preterm birth (&lt;37\u2009weeks) was much more common in women with SCD (28.5% vs. 5.6%). Infants born to women with SCD faced greater adverse neonatal outcomes (22.4% vs. 8.0%; <em>p<\/em>\u2009&lt;\u20090.001). Although untreated SCD was linked to fewer complications than long-term treated SCD, both conditions presented greater risks compared with pregnancies without SCD. Unexpectedly, babies born to women with SCD had a higher incidence of congenital abnormalities (6.3% vs. 3.4%; <em>p<\/em>\u2009&lt;\u20090.001), not attributed to HU use. Overall, despite advances in SCD management, pregnancy in SCD remains a high-risk condition, for both mothers and babies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Br J Haematol. 2025 Apr;206(4):1218-1227<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-8573","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"Br J Haematol. 2025 Apr;206(4):1218-1227\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T15:01:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/\",\"name\":\"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\"},\"datePublished\":\"2025-04-01T14:57:09+00:00\",\"dateModified\":\"2025-07-04T15:01:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.instagram.com\/fhupremimpact\/\",\"https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/","og_locale":"en_US","og_type":"article","og_title":"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT","og_description":"Br J Haematol. 2025 Apr;206(4):1218-1227","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2025-07-04T15:01:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/","name":"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France. - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2025-04-01T14:57:09+00:00","dateModified":"2025-07-04T15:01:13+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/maternal-and-perinatal-outcomes-of-sickle-cell-disease-in-pregnancy-a-nationwide-study-in-france\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France."}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Br J Haematol. 2025 Apr;206(4):1218-1227","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/8573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=8573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}